UBS Group
BNGO icon

UBS Group’s Bionano Genomics BNGO Stock Holding History

UBS Group’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19 Sell
16
-9,043
-100% -$11.6K ﹤0.01% 10298
2025
Q4 		$13.9K Sell
9,059
-54,817
-86% -$94.9K ﹤0.01% 8033
2025
Q3 		$109K Buy
63,876
+61,206
+2,292% +$195K ﹤0.01% 7056
2025
Q2 		$8.76K Buy
2,670
+297
+13% +$1.11K ﹤0.01% 8924
2025
Q1 		$6.62K Sell
2,373
-42
-2% -$275 ﹤0.01% 8887
2024
Q4 		$41.7K Buy
2,415
+2,414
+241,400% +$41.3K ﹤0.01% 7409
2024
Q3 		$35 Hold
1
– – ﹤0.01% 9264
2024
Q2 		$54 Sell
1
-142
-99% -$7.8K ﹤0.01% 9226
2024
Q1 		$9.5K Buy
143
+138
+2,760% +$10.3K ﹤0.01% 7281
2023
Q4 		$574 Sell
5
-183
-97% -$19.1K ﹤0.01% 8582
2023
Q3 		$34.1K Sell
188
-18
-9% -$4.72K ﹤0.01% 6525
2023
Q2 		$75.4K Sell
206
-81
-28% -$36.6K ﹤0.01% 6215
2023
Q1 		$191K Buy
287
+230
+404% +$204K ﹤0.01% 5414
2022
Q4 		$50.3K Buy
57
+53
+1,325% +$66.7K ﹤0.01% 6771
2022
Q3 		$4K Sell
4
-82
-95% -$108K ﹤0.01% 9334
2022
Q2 		$72K Sell
86
-14
-14% -$14.4K ﹤0.01% 5660
2022
Q1 		$155K Sell
100
-125
-56% -$169K ﹤0.01% 5564
2021
Q4 		$404K Buy
225
+213
+1,775% +$570K ﹤0.01% 5155
2021
Q3 		$39K Buy
12
+2
+20% +$7K ﹤0.01% 6532
2021
Q2 		$44K Sell
10
-42
-81% -$166K ﹤0.01% 6545
2021
Q1 		$252K Buy
52
+38
+271% +$214K ﹤0.01% 5320
2020
Q4 		$26K Sell
14
-134
-91% -$50.1K ﹤0.01% 6742
2020
Q3 		$58K Sell
148
-183
-55% -$70.9K ﹤0.01% 5534
2020
Q2 		$101K Buy
331
+245
+285% +$61.5K ﹤0.01% 5296
2020
Q1 		$24K Buy
86
+69
+406% +$39K ﹤0.01% 6367
2019
Q4 		$12K Buy
+17
New +$9.94K ﹤0.01% 7176
2019
Q3 		– Hold
0
– -$1K – 7998
2019
Q2 		– Hold
0
– – – 7701

Other funds holding BNGO

GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Carret Asset Management New York $1.14B AUM 35.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group's BNGO Position: Q1 2026 in Review

UBS Group reduced its Bionano Genomics (BNGO) stake by 100% in Q1 2026, selling an estimated $11.6K and leaving 16 shares worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #10298.

UBS Group first reported a position in BNGO in Q4 2019 and has held it in 26 quarters since. The position peaked at $404K in Q4 2021. 32 funds tracked by Wall St. Rank hold BNGO as of Q1 2026.

  • UBS Group held 16 shares of Bionano Genomics worth $19 as of Q1 2026.
  • UBS Group sold 9,043 Bionano Genomics shares in Q1 2026, an estimated $11.6K.
  • Bionano Genomics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10298 holding.
  • UBS Group first reported a position in Bionano Genomics in Q4 2019 and has held it in 26 quarters since.
  • UBS Group's Bionano Genomics position peaked at $404K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.